维普中文期刊产品整合服务

An Open-Label Study of Pegylated Liposomal Doxorubicin,Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese Population

查看全文 作　　者：Yang [1]Shen;Zhixiang [1]Shen;Bin [2]Jiang;Jian [3]Hou;Rong [4]Zhan;Lugui [5]Qiu;Daobin [6]Zhou;Jie [7]Jin;Juan [8]Li;Fanyi [9]Meng;Ping [10]Zou;Ting [11]Liu;Jianyong [12]Li;Chun [13]Wang;Depei [14]Wu;Jun [15]Ma 高影响力作者 机构地区：[1]Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University, Medical School, Shanghai, China;[2]Department of Hematology, People's Hospital Affiliated to Beijing University, Beijing, China;[3]Department of Hematology, Shanghai Changzheng Hospital, Shanghai, China;[4]Department of Hematology, Affiliated Union Hospital of Fujian Medical Uni- versity, Fujian, Fuzhou Province, China;[5]Department of Hematology, Institute of Hematology and Blood Disease Hospital of Chinese Academy of Medical Sciences, Beijing, China;[6]Department of Hematology, Peking Union Medical College Hospital, Bei- jing, China;[7]Department of Hematology, 1st Affiliated Hospital of Zhejiang University, Han.qzhou, Zheiing Province, China;[8]Department of Hematology, The First Affiliated Hospital, Sun Yat-Sen Uni- versity, Guangzhou, Guangdong Province, China;[9]Department of Hematology, Nanfang Medical University Affiliated Nanfang Hospital, Guangzhou, Guangdong Province,China;[10]Department of Hematology, Wuhan Union Hospital, Wuhan, Hubei Province. China;[11]Department of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China;[12]Department of Hematology, The People's Hospital of Jiangsu Province Nanjing, Jiangsu Province, China;[13]Department of Hematology, Shanghai First People's Hospital, Shanghai, China;[14]Department of Hematology, the First Affiliated Hospital of Suzhou University, Suzhou, Zhejing Province, China;[15]Department of Hematology, Harbin Institute of Hematology & Oncology, Harbin, Heilongjiang Province, China高影响力机构 出　　处：《Clinical oncology and cancer resexreh》索引2009年第6卷第6期,共7页高影响力期刊 摘　　要：OBJECTIVE Though doxorubicin is highly activein the treatment of multiple myeloma, its toxicityprofile limits its therapeutic index. We performed thisstudy to evaluate the efficacy and safety of pegylatedliposomal doxorubicin (PLD, Caelyx^(?)), vincristine,and reduced-dose dexamethasone combinationtherapy in newly diagnosed multiple myeloma (MM)patients in a Chinese population.METHODS This was an open-label, single-armstudy in which newly diagnosed patients with MMreceived PLD 40 mg/m^2 intravenously on Day 1,vincristine 1.4 mg/m^2 intravenously (maximum 2 mg)on Day 1, and 40 mg of dexarnethasone (intravenouslyor orally) from Day 1 to Day 4. Treatment wasrepeated every 28 days for at least 4 cycles.RESULTS In the intent-to-treat (ITT) analysis, theoverall response rate was 68.29%, and the completeremission rate was 10.98%. The incidence of alladverse events was 46.34%. The most commonnon-hematologic toxicities were palmar-plantarerythrodysesthesia (13.4%) and stomatitis (6.1%).CONCLUSION PLD, vincristine, and a reduceddosedexamethasone combination (DVd) is aneffective and safe regimen in newly diagnosed MMpatients in a Chinese population. 关 键 词：多发性骨髓瘤 联合治疗 长春新碱 地塞米松 中国人口 聚乙二醇 阿霉素 脂质体
相关文献

参考文献(10)

引证文献(1)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费